Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Oncología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Completado
ClinicalTrials.gov
Correlate - Safety and Effectiveness of Regorafenib in Routine Clinical Practice Settings
OBSERVATIONAL
Inicio: 8 de abr de 2014
ID: NCT02042144
Activo, no recluta
Fase 3
ClinicalTrials.gov
LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
INTERVENTIONAL
Inicio: 17 de feb de 2020
ID: NCT04194944
Terminado
Fase 3
ClinicalTrials.gov
A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients With HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab With Chemotherapy Plus Trastuzumab Plus Bevacizumab
INTERVENTIONAL
Inicio: 1 de abr de 2008
ID: NCT00625898
Reclutando
Fase 3
ClinicalTrials.gov
CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease
INTERVENTIONAL
Inicio: 5 de oct de 2023
ID: NCT05952557
Terminado
Fase 3
ClinicalTrials.gov
EPIK-O: A Phase III, Multi-center, Randomized (1:1), Open-label, Active-controlled, Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Olaparib as Compared to Single Agent Cytotoxic Chemotherapy, in Participants With no Germline BRCA Mutation Detected, Platinum-resistant or Refractory, High-grade Serous Ovarian Cancer
INTERVENTIONAL
Inicio: 22 de jul de 2021
ID: NCT04729387
Reclutando
Fase 3
ClinicalTrials.gov
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib Plus a CDK4/6 Inhibitor and Letrozole Versus Placebo Plus a CDK4/6 Inhibitor and Letrozole in Patients With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
INTERVENTIONAL
Inicio: 9 de abr de 2025
ID: NCT06790693
Completado
Fase 2
ClinicalTrials.gov
A Randomized, Open-label, Dose-escalation to Rash Study to Assess the Effect of Tarceva in Combination With Gemcitabine on Overall Survival in Patients With Metastatic Pancreatic Cancer.
INTERVENTIONAL
Inicio: 1 de may de 2008
ID: NCT00652366
Completado
Fase 3
ClinicalTrials.gov
A Multinational, Randomized, Double-blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks Versus Placebo in Patients With Metastatic Colorectal Cancer (MCRC) Treated With Irinotecan / 5-FU Combination (FOLFIRI) After Failure of an Oxaliplatin Based Regimen
INTERVENTIONAL
Inicio: 1 de nov de 2007
ID: NCT00561470
Completado
Fase 2
ClinicalTrials.gov
Phase II Study of Novel Epothilone (BMS-247550) in Patients With MBC Who Are Refractory to an Anthracycline, a Taxane, and Capecitabine
INTERVENTIONAL
Inicio: 1 de feb de 2004
ID: NCT00080262
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009)
INTERVENTIONAL
Inicio: 21 de oct de 2024
ID: NCT06623422
Completado
Fase 2
ClinicalTrials.gov
A Phase 2, Multicenter, Randomized Study to Compare the Efficacy and Safety of MK-7684A or MK-7684A Plus Docetaxel Versus Docetaxel Monotherapy in the Treatment of Participants With Metastatic Non-small Cell Lung Cancer With Progressive Disease After Treatment With a Platinum Doublet Chemotherapy and Immunotherapy
INTERVENTIONAL
Inicio: 20 de abr de 2021
ID: NCT04725188
Completado
Fase 2
ClinicalTrials.gov
An Open Label, Stratified, Single-arm Phase II Study of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumor (NET) After Failure of Cytotoxic Chemotherapy
INTERVENTIONAL
Inicio: 1 de jun de 2006
ID: NCT00363051
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Open-Label, Phase III Study of RPR109881 IV Every 3 Weeks Versus Capecitabine (Xeloda) Tablets Twice Daily for 2 Weeks in 3-Week Cycles in Patients With Metastatic Breast Cancer Progressing After Taxanes and Anthracycline Therapy
INTERVENTIONAL
Inicio: 1 de abr de 2004
ID: NCT00081796
Desconocido
ClinicalTrials.gov
Multicentric Study of Cervical Cancer Screening and Triage With Human Papillomavirus (HPV) Testing
OBSERVATIONAL
Inicio: 1 de may de 2013
ID: NCT01881659
Completado
Fase 2
ClinicalTrials.gov
A Phase II, Single Arm, Open Label Study of Treatment-free Remission in Chronic Myeloid Leukemia (CML) Chronic Phase (CP) Patients After Achieving Sustained MR4.5 on Nilotinib
INTERVENTIONAL
Inicio: 20 de dic de 2012
ID: NCT01698905
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3, Open-label, Randomized Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Patients With EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer After Progression on Osimertinib and Chemotherapy
INTERVENTIONAL
Inicio: 5 de ago de 2022
ID: NCT05388669
Completado
Fase 3
ClinicalTrials.gov
A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Paclitaxel or Atezolizumab in Combination With Carboplatin+Nab-Paclitaxel Versus Carboplatin+Nab-Paclitaxel in Chemotherapy-Naive Patients With Stage IV Squamous Non-Small Cell Lung Cancer
INTERVENTIONAL
Inicio: 11 de jun de 2015
ID: NCT02367794
Completado
Fase 2
ClinicalTrials.gov
A Phase 1/2 Study Of Bosutinib (Ski-606) In Philadelphia Chromosome Positive Leukemias
INTERVENTIONAL
Inicio: 18 de ene de 2006
ID: NCT00261846
Completado
Fase 2
ClinicalTrials.gov
A Phase 2 Study of Alimta and Epirubicin Administered Every 21 Days in Patients With Locally Advanced or Metastatic Breast Cancer
INTERVENTIONAL
ID: NCT00097383
Completado
Fase 3
ClinicalTrials.gov
A Double Blind, Randomized, Phase II-III Maintenance Study of SR48692 Versus Placebo in Patients With Extensive Stage Small Cell Lung Cancer Following a First Line Chemotherapy With Cisplatin + Etoposide
INTERVENTIONAL
Inicio: 1 de oct de 2002
ID: NCT00290953
Anterior
1
...
52
53
54
...
434
Siguiente
Filtros